Last reviewed 2026-04-20 · How we verify

Divascan (IPRAZOCHROME)

Phase 2 active Small molecule

Divascan (generic name: IPRAZOCHROME) is a iprazochrome drug. It is currently in Phase 2 development.

Divascan works by binding to specific proteins in the body to produce its therapeutic effects.

Divascan (IPRAZOCHROME) is a small molecule drug in the iprazochrome class, but details about its target, FDA approval status, and approved indications are unknown. As a small molecule, it is designed to interact with specific biological targets to produce its therapeutic effects. The commercial status of Divascan is also unclear, with no information available on whether it is patented or available as a generic. Further research is needed to understand the safety considerations and potential side effects of this medication. Overall, more information is required to fully assess the characteristics and potential uses of Divascan.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IPRAZOCHROME
Drug class	iprazochrome
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Divascan is a key that fits into those locks. When it binds to the right lock, it helps to turn the lock and unlock the cell's normal functioning, which can help to treat certain medical conditions. This process is called a pharmacological interaction, and it's how many medications work to produce their effects.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Divascan CI brief — competitive landscape report
Divascan updates RSS · CI watch RSS

Frequently asked questions about Divascan

What is Divascan?

Divascan (IPRAZOCHROME) is a iprazochrome drug.

How does Divascan work?

Divascan works by binding to specific proteins in the body to produce its therapeutic effects.

What is the generic name of Divascan?

IPRAZOCHROME is the generic (nonproprietary) name of Divascan.

What drug class is Divascan in?

Divascan belongs to the iprazochrome class. See all iprazochrome drugs at /class/iprazochrome.

What development phase is Divascan in?

Divascan is in Phase 2.

Drug class: All iprazochrome drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing